Literature DB >> 3130476

Mechanisms for the pharmacologic interaction of organic nitrates with thiols. Existence of an extracellular pathway for the reversal of nitrate vascular tolerance by N-acetylcysteine.

H L Fung1, S Chong, E Kowaluk, K Hough, M Kakemi.   

Abstract

Recent reports have shown that the coadministration of N-acetylcysteine (NAC) potentiated the hemodynamic actions of i.v. nitroglycerin (NTG) and reversed NTG tolerance in humans. This study has investigated the feasibility of various pharmacokinetic and biochemical mechanisms for the thiol-organic nitrate interaction, using the rat as an animal model. In order to establish that the potentiating interaction between NAC and NTG can be reproduced in the rat, NTG dose-blood pressure response curves were determined before and during concurrent thiol infusion. The hypotensive effect of NTG was enhanced significantly by NAC and glutathione, but not by N-acetylserine, showing clearly that the potentiating effect of NAC was due specifically to its thiol functional group. The systemic clearance of NTG was not affected significantly by NAC coinfusion. In addition, the intracellular metabolism of NTG in thoracic aorta segments from rats infused previously with NAC or N-acetylserine was similar, both with respect to total production of metabolites and their distribution. Thus, the enhancement of NTG action could not be attributed apparently to an effect of NAC on NTG systemic pharmacokinetics or vascular metabolism of NTG. Because glutathione, which does not enter cells readily, also potentiated the effects of NTG, the possibility of an extracellular pathway for the thiol-organic nitrate interaction was examined. In vitro degradation of NTG in plasma and blood was accelerated in the presence of NAC (or glutathione). NAC also promoted the formation of S-nitroso-N-acetylcysteine from NTG in rat and human plasma and human blood.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3130476

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

1.  Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts.

Authors:  Pei-Suen Tsou; Nadine N Talia; Adam J Pinney; Ann Kendzicky; Sonsoles Piera-Velazquez; Sergio A Jimenez; James R Seibold; Kristine Phillips; Alisa E Koch
Journal:  Arthritis Rheum       Date:  2011-12-12

Review 2.  Avoiding nitrate tolerance.

Authors:  J C Cowan
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

Review 3.  Mechanisms of nitrate tolerance: a review.

Authors:  R J Katz
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 4.  Update on nitrate tolerance.

Authors:  J O Parker
Journal:  Br J Clin Pharmacol       Date:  1992       Impact factor: 4.335

Review 5.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 6.  Mechanisms of action of nitrates.

Authors:  K E Torfgård; J Ahlner
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

7.  Vascular and anti-platelet actions of 1,2- and 1,3-glyceryl dinitrate.

Authors:  D Salvemini; A Pistelli; E Anggard
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

Review 8.  Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic nitrate esters.

Authors:  L J Ignarro
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

9.  S-nitrosothiols as vasodilators: implications regarding tolerance to nitric oxide-containing vasodilators.

Authors:  P J Henry; O H Drummer; J D Horowitz
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

10.  Chemical stabilization of a vasoactive S-nitrosothiol with cyclodextrins without loss of pharmacologic activity.

Authors:  J A Bauer; H L Fung
Journal:  Pharm Res       Date:  1991-10       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.